Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol. 2008;8:380–90.
Van Vlierberghe P, Ferrando A. The molecular foundation of T cell acute lymphoblastic leukemia. J Clin Make investments. 2012;122:3398–406.
Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Most cancers. 2016;16:494–507.
Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, threat stratification, and remedy of pediatric acute leukemias: an replace. J Clin Oncol. 2011;29:551–65.
Patel AA, Thomas J, Rojek AE, Inventory W. Biology and therapy paradigms in T cell acute lymphoblastic leukemia in older adolescents and adults. Curr Deal with Choices Oncol. 2020;21:57.
Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005;23:6306–15.
Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic panorama of pediatric and younger grownup T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49:1211–8.
Weng AP, Ferrando AA, Lee W, Morris JPT, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269–71.
Tan SH, Bertulfo FC, Sanda T. Leukemia-initiating cells in T-cell acute lymphoblastic leukemia. Entrance Oncol. 2017;7:218.
Weng Y, Khatri B, Hong G, Wang F, Chen Z, Huang Q. Protecting impact of interleukin-1beta on motor neurons after sciatic nerve damage in rats. J Huazhong Univ Sci Technol Med Sci. 2004;24:71–4.
Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, et al. A NOTCH1-driven MYC enhancer promotes T cell growth, transformation and acute lymphoblastic leukemia. Nat Med. 2014;20:1130–7.
Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, et al. Core transcriptional regulatory circuit managed by the TAL1 complicated in human T cell acute lymphoblastic leukemia. Most cancers Cell. 2012;22:209–21.
Liau WS, Tan SH, Ngoc PCT, Wang CQ, Tergaonkar V, Feng H, et al. Aberrant activation of the GIMAP enhancer by oncogenic transcription elements in T-cell acute lymphoblastic leukemia. Leukemia. 2017;31:1798–807.
Hanahan D. Hallmarks of most cancers: new dimensions. Most cancers Discov. 2022;12:31–46.
Kadoch C, Crabtree GR. Mammalian SWI/SNF chromatin transforming complexes and most cancers: Mechanistic insights gained from human genomics. Sci Adv. 2015;1:e1500447.
Mittal P, Roberts CWM. The SWI/SNF complicated in most cancers – biology, biomarkers and remedy. Nat Rev Clin Oncol. 2020;17:435–48.
Clapier CR, Iwasa J, Cairns BR, Peterson CL. Mechanisms of motion and regulation of ATP-dependent chromatin-remodelling complexes. Nat Rev Mol Cell Biol. 2017;18:407–22.
Heng TS, Painter MW, Immunological Genome Undertaking C. The Immunological Genome Undertaking: networks of gene expression in immune cells. Nat Immunol. 2008;9:1091–4.
Corces MR, Buenrostro JD, Wu B, Greenside PG, Chan SM, Koenig JL, et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat Genet. 2016;48:1193–203.
DepMap, Broad. This DepMap launch comprises information from CRISPR knockout screens from mission Achilles, in addition to genomic characterization information from the CCLE mission. For extra info, please see README.txt. figshare. Dataset. 2023.
Békés M, Langley DR, Crews CM. PROTAC focused protein degraders: the previous is prologue. Nat Rev Drug Discov. 2022;21:181–200.
Xiao L, Parolia A, Qiao Y, Bawa P, Eyunni S, Mannan R, et al. Focusing on SWI/SNF ATPases in enhancer-addicted prostate most cancers. Nature. 2022;601:434–9.
Draheim KM, Hermance N, Yang Y, Arous E, Calvo J, Kelliher MA. A DNA-binding mutant of TAL1 cooperates with LMO2 to trigger T cell leukemia in mice. Oncogene. 2011;30:1252–60.
Papillon JPN, Nakajima Ok, Adair CD, Hempel J, Jouk AO, Karki RG, et al. Discovery of orally energetic inhibitors of brahma homolog (BRM)/SMARCA2 ATPase exercise for the therapy of Brahma associated gene 1 (BRG1)/SMARCA4-mutant cancers. J Med Chem. 2018;61:10155–72.
Shi J, Whyte WA, Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe JS, et al. Position of SWI/SNF in acute leukemia upkeep and enhancer-mediated Myc regulation. Genes Dev. 2013;27:2648–62.
O’Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204:1813–24.
Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway maintain major T cell leukemia viability. J Clin Make investments. 2008;118:3762–74.
Schick S, Grosche S, Kohl KE, Drpic D, Jaeger MG, Marella NC, et al. Acute BAF perturbation causes speedy modifications in chromatin accessibility. Nat Genet. 2021;53:269–78.
Kloetgen A, Thandapani P, Ntziachristos P, Ghebrechristos Y, Nomikou S, Lazaris C, et al. Three-dimensional chromatin landscapes in T cell acute lymphoblastic leukemia. Nat Genet. 2020;52:388–400.
Yatim A, Benne C, Sobhian B, Laurent-Chabalier S, Deas O, Judde JG, et al. NOTCH1 nuclear interactome reveals key regulators of its transcriptional exercise and oncogenic operate. Mol Cell. 2012;48:445–58.
Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, et al. Proteomic and bioinformatic evaluation of mammalian SWI/SNF complexes identifies intensive roles in human malignancy. Nat Genet. 2013;45:592–601.
Choi A, Illendula A, Pulikkan JA, Roderick JE, Tesell J, Yu J, et al. RUNX1 is required for oncogenic Myb and Myc enhancer exercise in T-cell acute lymphoblastic leukemia. Blood. 2017;130:1722–33.
Schneider M, Radoux CJ, Hercules A, Ochoa D, Dunham I, Zalmas LP, et al. The PROTACtable genome. Nat Rev Drug Discov. 2021;20:789–97.
Zhao L, Zhao J, Zhong Ok, Tong A, Jia D. Focused protein degradation: mechanisms, methods and utility. Sign Transduct Goal Ther. 2022;7:113.
Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes concerned in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267–73.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment evaluation: a knowledge-based method for deciphering genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50.
Mumbach MR, Rubin AJ, Flynn RA, Dai C, Khavari PA, Greenleaf WJ, et al. HiChIP: environment friendly and delicate evaluation of protein-directed genome structure. Nat Strategies. 2016;13:919–22.
Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. ATAC-seq: a way for assaying chromatin accessibility genome-wide. Curr Protoc Mol Biol. 2015;109:21.9.1–9.9.
Abraham BJ, Hnisz D, Weintraub AS, Kwiatkowski N, Li CH, Li Z, et al. Small genomic insertions type enhancers that misregulate oncogenes. Nat Commun. 2017;8:14385.
Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren B, Milosavljevic A, Meissner A, et al. The NIH roadmap epigenomics mapping consortium. Nat Biotechnol. 2010;28:1045–8.
Vahedi G, Kanno Y, Furumoto Y, Jiang Ok, Parker SC, Erdos MR, et al. Tremendous-enhancers delineate disease-associated regulatory nodes in T cells. Nature. 2015;520:558–62.
Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, et al. Focusing on transcription regulation in most cancers with a covalent CDK7 inhibitor. Nature. 2014;511:616–20.
